Table 2.

Associations of plasma biomarkers and WMH with age-residualized NfL concentrations across diagnostic groups

	Whole Sample		Cognitively Stable		MCI		Dementia		Undetermined
	r [CI]	p-value	r [CI]	p-value	r [CI]	p-value	r [CI]	p-value	r [CI]	p-value
WMH volume	0.32 [0.18, 0.44]	<0.0001	0.14 [−0.03, 0.30]	0.10	0.62 [0.23, 0.80]	0.003	0.42 [0.18, 0.85]	0.12	0.44 [−0.39, 0.87]	0.32
Aβ42/40	0.14 [−0.01, 0.28]	0.06	0.12 [−0.05, 0.28]	0.18	−0.14 [−0.52, 0.28]	0.51	0.31 [−0.22, 0.70]	0.24	−0.41 [−0.87, 0.41]	0.31
p-tau217	0.52 [0.41, 0.62]	<0.0001	0.10 [−0.07, 0.26]	0.25	0.86 [0.70, 0.94]	<0.0001	0.82 [0.55, 0.94]	<0.0001	0.21 [−0.58, 0.80]	0.61
GFAP	0.31 [0.18, 0.44]	<0.0001	0.09 [−0.081, 0.25]	0.31	0.47 [0.08, 0.74]	0.02	0.62 [0.25, 0.87]	0.005	0.19 [−0.59, 0.79]	0.65

Aβ: β-amyloid, WMH: white matter hyperintensities, p-tau217: phosphorylated tau 217, GFAP: glial fibrillary acidic protein, NfL: neurofilament light chain, MCI: mild cognitive impairment